MATCH cohort provides regulatory-ready external control framework for MSUD gene therapy trials
By
Kevin A. Strauss1,2,3 Send email to [email protected]
Summary
This article presents the MSUD Age-matched Standard Treatment Cohort (MATCH), a prospective natural history study of 11 infants with classic maple syrup urine disease (MSUD) followed from neonatal diagnosis to liver transplantation. Designed as a regulatory-ready external control for gene therapy trials, MATCH aligns with FDA guidance and ICH E9(R1) standards, applying prespecified eligibility criteria, fixed visit cadence, adjudicated outcomes, and explicit handling of intercurrent events. The authors demonstrate through Monte Carlo simulations how protocolized natural history data can serve as quantitative evidence supporting ethically defensible single-arm trials in rare diseases where randomized controlled trials are infeasible.
Source
bskyMATCH cohort provides regulatory-ready external control framework for MSUD gene therapy trialscell.comKey quotes
· 3 pulledMaple syrup urine disease (MSUD) is a life-threatening metabolic disorder for which randomized trials are infeasible.
MATCH applies prespecified eligibility criteria, fixed visit cadence, adjudicated outcomes, and explicit handling of intercurrent events.
The authors demonstrate how protocolized data can serve as quantitative evidence supporting ethically defensible single-arm trials.
You might also wanna read
FDA Clears NIH-Supported Gene Therapy MMA-101 for First Human Trial in Rare Metabolic Disorder
The FDA has cleared an Investigational New Drug (IND) application for MMA-101, an AAV-based gene therapy candidate developed with NIH suppor

FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
Study Finds Household Cohabitation, Not Genetics, Drives Transmission of Diabetes- and Cancer-Linked Microbes
Researchers mapped the environmental and physical dynamics of human microbiome transmission, proving that household cohabitation is the prim

Age engineering: Creating age-matched tissues for better biomedical models of ageing
This article discusses the emerging field of 'age engineering' or 'ageneering' — the methodological approach to engineering the age of tissu

AAV-mediated FGF21 gene therapy extends health span and lifespan in aged mice through multi-tissue adaptations
This study demonstrates that a one-time muscle-directed AAV-mediated FGF21 gene therapy in aged and geriatric mice extends health span and l

Comments
Sign in to join the conversation.
No comments yet. Be the first.